Site navigation

Navigation

Asthma (uncontrolled) - omalizumab

Omalizumab for severe persistent allergic asthma

Summary

Omalizumab is recommended as a possible treatment for adults and young people over 12 years with severe persistent allergic asthma when all of the following circumstances apply. When the person's asthma is still severe and unstable despite best efforts to control it with other asthma medicines t ...

Read the complete summary


Guidance documents

Implementing this guidance

Other information

We will consult on our review plans for this guidance in August 2010

About this guidance

Technology appraisals TA133

Issued: November 2007

How this guidance was produced

See also:

See this guidance in practice:

Order printed copies of this guidance